Patents by Inventor Andreas Machl

Andreas Machl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MIXED-PLASTICS-POLYPROPYLENE BLEND
    Publication number: 20240093012
    Abstract: Mixed-plastics polypropylene blend including mainly polypropylene being benzene free with defined CIELAB color.
    Type: Application
    Filed: March 25, 2022
    Publication date: March 21, 2024
    Inventors: Tuan Anh Tran, Susana Lopes Filipe, Andreas Nagl, Doris Machl, Andreas Rössler-Czermak
  • KINASE INHIBITOR COMBINATIONS FOR CANCER TREATMENT
    Publication number: 20240024324
    Abstract: A combination includes 4-[(S)-2-Azetidin-1-yl-1-(4-chloro-3-trifluoromethyl-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide and/or its physiologically acceptable salts and solvates, an inhibitor of MEK kinase, and as an optional third inhibitor, an inhibitor of EGFR. The combination is useful for the treatment of cancer. Another combination includes 4-[(S)-2-Azetidin-1-yl-1-(4-chloro-3-trifloromethyl-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide and/or its physiologically acceptable salts and solvates, and an inhibitor of EGFR.
    Type: Application
    Filed: November 15, 2021
    Publication date: January 25, 2024
    Inventors: Anderson Clark, Andreas Machl, Bayard Huck, Erik Wilker, Remigiusz Kaleta
  • Combinations of cancer therapeutics
    Patent number: 9980966
    Abstract: The invention relates to combinations of 4-[(S)-2-Azetidin-1-yl-1-(4-chloro-3-trifluoromethyl-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide and/or its physiologically acceptable salts and solvates, and an inhibitor of Her2, and the use of such combinations for the treatment of cancer.
    Type: Grant
    Filed: March 9, 2015
    Date of Patent: May 29, 2018
    Assignee: Merck Patent GmbH
    Inventors: Bayard R. Huck, Erik Wilker, Andreas Machl, Remigiusz Kaleta
  • COMBINATIONS OF CANCER THERAPEUTICS
    Publication number: 20170100402
    Abstract: The invention relates to combinations of 4-[(S)-2-Azetidin-1-yl-1-(4-chloro-3-trifluoromethyl-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide and/or its physiologically acceptable salts and solvates, and an inhibitor of Her2, and the use of such combinations for the treatment of cancer.
    Type: Application
    Filed: March 9, 2015
    Publication date: April 13, 2017
    Inventors: Bayard R. HUCK, Erik WILKER, Andreas MACHL, Remigiusz KALETA
  • Fanconi-gen II
    Publication number: 20030022858
    Abstract: The present invention concerns a pathophysiologically relevant gene associated with Fanconi anaemia (FA), a polypeptide coded thereby, an antibody directed against the polypeptide as well as the pharmaceutical applications of the nucleic acid, polypeptide and antibody.
    Type: Application
    Filed: July 19, 2002
    Publication date: January 30, 2003
    Inventors: Manfred Kubbies, Andreas Machl, Simone Planitzer
  • Fanconi-gene II
    Publication number: 20020086848
    Abstract: The present invention concerns a pathophysiologically relevant gene associated with Fanconi anaemia (FA), a polypeptide coded thereby, an antibody directed against the polypeptide as well as the pharmaceutical applications of the nucleic acid, polypeptide and antibody.
    Type: Application
    Filed: October 15, 2001
    Publication date: July 4, 2002
    Inventors: Manfred Kubbies, Andreas Machl, Simone Planitzer